Everett Cunningham - Quest Diagnostics Senior Vice President - Commercial
| DGX Stock | USD 128.64 0.11 0.09% |
President
Mr. Everett V. Cunningham is Senior Vice President Commercial of the Company. Mr. Cunningham is responsible for the commercial organization for the Company Diagnostic Information Services business. Prior to joining the Company in October 2012, he spent 21 years with Pfizer, Inc., where he served from June 2011 to October 2012 as Regional President, Established Products, Asia. From 2009 to 2011, Mr. Cunningham served as Regional President, West Business Unit, Primary Care. From 2007 to 2009, he served as Vice President, Human Resources, Corporationrationrate Groups. Before that Mr. Cunningham served Pfizer in a series of sales and leadership and general management roles. since 2012.
| Age | 51 |
| Tenure | 12 years |
| Address | 500 Plaza Drive, Secaucus, NJ, United States, 07094 |
| Phone | 973 520 2700 |
| Web | https://www.questdiagnostics.com |
Quest Diagnostics Management Efficiency
The company has Return on Asset of 0.0621 % which means that on every $100 spent on assets, it made $0.0621 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1462 %, implying that it generated $0.1462 on every 100 dollars invested. Quest Diagnostics' management efficiency ratios could be used to measure how well Quest Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to 0.14 in 2024. Return On Capital Employed is likely to drop to 0.10 in 2024. At this time, Quest Diagnostics' Other Assets are fairly stable compared to the past year. Asset Turnover is likely to rise to 0.99 in 2024, whereas Total Assets are likely to drop slightly above 8.5 B in 2024.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Pat Venters | IDEXX Laboratories | N/A | |
| Wendy Stewart | IQVIA Holdings | N/A | |
| Mark Beaudouin | Waters | 63 | |
| David Johst | Charles River Laboratories | 57 | |
| Michael Harrington | Waters | 59 | |
| Ian King | Waters | 63 | |
| Dominique Grau | Agilent Technologies | 65 | |
| Robert McMahon | Agilent Technologies | 55 | |
| Michael McDonnell | IQVIA Holdings | 55 | |
| Patrick Kaltenbach | Agilent Technologies | 53 | |
| Kathy Turner | IDEXX Laboratories | 54 | |
| Nilton Paletta | IQVIA Holdings | N/A | |
| Michael Knell | Charles River Laboratories | 47 | |
| Martin Kunz | Twist Bioscience Corp | 47 | |
| Richard Staub | IQVIA Holdings | 54 | |
| Robert Carson | Waters | 46 | |
| Simon Holmes | ICON PLC | 57 | |
| Nancy Gillett | Charles River Laboratories | 58 | |
| Cynthia Verst | IQVIA Holdings | N/A | |
| Richard III | IQVIA Holdings | 61 | |
| Rohit Khanna | Waters | 58 | |
Management Performance
| Return On Equity | 0.15 | ||||
| Return On Asset | 0.0621 |
Quest Diagnostics Leadership Team
Elected by the shareholders, the Quest Diagnostics' board of directors comprises two types of representatives: Quest Diagnostics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Quest. The board's role is to monitor Quest Diagnostics' management team and ensure that shareholders' interests are well served. Quest Diagnostics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Quest Diagnostics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Patrick Plewman, Senior Services | ||
| Gail Wilensky, Independent Director | ||
| Kristin Esq, Senior Officer | ||
| Stephen Rusckowski, CEO and President Director and Member of Executive Committee | ||
| Wright Lassiter, Independent Director | ||
| Gary Pfeiffer, Independent Director | ||
| Vicky Gregg, Independent Director | ||
| Cecilia McKenney, Senior Officer | ||
| Helen Torley, Independent Director | ||
| Michael Prevoznik, Senior Vice President General Counsel | ||
| Tracey Doi, Independent Director | ||
| John Ziegler, Independent Director | ||
| Karthik Kuppusamy, Senior Solutions | ||
| John Baldwin, Independent Director | ||
| Jon Cohen, Senior Vice President Chief Medical Officer | ||
| Catherine Doherty, Senior Vice President, Group Executive - Clinical Franchise Solutions and Marketing | ||
| Manuel Mendez, Senior Vice President Chief Commercial Officer | ||
| Gabrielle Wolfson, Senior Vice President and Chief Information and Digital Officer | ||
| Carrie Manner, Senior Vice President - Advanced Diagnostics | ||
| Sam Samad, Executive CFO | ||
| Dermot Shorten, MA Strategy | ||
| Jenne Britell, Independent Director | ||
| Shawn Bevec, Executive Director Investor Relations | ||
| Dan Haemmerle, Executive Director - Investor Relations | ||
| Timothy Main, Independent Director | ||
| Michael Deppe, Vice President Corporate Controller and Chief Accounting Officer and Principal Accounting Officer | ||
| Everett Cunningham, Senior Vice President - Commercial | ||
| Mark Guinan, Chief Financial Officer, Executive Vice President | ||
| Daniel Stanzione, Non-Executive Chairman of the Board | ||
| Gary Samuels, Senior Officer | ||
| Denise Morrison, Independent Director | ||
| James Davis, Executive Vice President, General Diagnostics | ||
| Jeffrey Leiden, Independent Director | ||
| Timothy Ring, Lead Independent Director |
Quest Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Quest Diagnostics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.15 | ||||
| Return On Asset | 0.0621 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.13 % | ||||
| Current Valuation | 19.16 B | ||||
| Shares Outstanding | 111.06 M | ||||
| Shares Owned By Insiders | 0.43 % | ||||
| Shares Owned By Institutions | 91.73 % | ||||
| Number Of Shares Shorted | 2.55 M | ||||
| Price To Earning | 14.57 X |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Quest Diagnostics Incorporated. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Quest Diagnostics information on this page should be used as a complementary analysis to other Quest Diagnostics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Complementary Tools for Quest Stock analysis
When running Quest Diagnostics' price analysis, check to measure Quest Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quest Diagnostics is operating at the current time. Most of Quest Diagnostics' value examination focuses on studying past and present price action to predict the probability of Quest Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quest Diagnostics' price. Additionally, you may evaluate how the addition of Quest Diagnostics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |
Is Quest Diagnostics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Quest Diagnostics. If investors know Quest will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Quest Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.868 | Dividend Share 2.84 | Earnings Share 7.49 | Revenue Per Share 82.607 | Quarterly Revenue Growth (0.02) |
The market value of Quest Diagnostics is measured differently than its book value, which is the value of Quest that is recorded on the company's balance sheet. Investors also form their own opinion of Quest Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Quest Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Quest Diagnostics' market value can be influenced by many factors that don't directly affect Quest Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Quest Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Quest Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Quest Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.